Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals

Acta Diabetologica

Volumn 46, Issue 1, 2009, Pages 13-21

  Bouchard, Luigi ^a,b   Faucher, Geneviève ^a,b   Tchernof, André ^a,b   Deshaies, Yves ^c   Lebel, Stéfane ^a   Hould, Frédéric Simon ^a   Marceau, Picard ^a   Vohl, Marie Claude ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Association study; Candidate gene; Diabetes; Metabolic syndrome; Polymorphism

Indexed keywords

CHOLESTEROL; COMPLEMENTARY DNA; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; RNA; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENETIC LINKAGE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; ANTIGENS, CD26; CARDIOVASCULAR DISEASES; DIASTOLE; EXONS; FEMALE; HUMANS; INCRETINS; LINKAGE DISEQUILIBRIUM; LIPIDS; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; OBESITY, MORBID; POLYMORPHISM, GENETIC; QUEBEC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 59449098931     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-008-0049-4     Document Type: Article

References (28)

1. AH Mokdad ES Ford BA Bowman 2003 Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001 JAMA 289 76 79
2. W Rosamond K Flegal G Friday 2007 Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 115 69 171
3. DJ Drucker MA Nauck 2006 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 1696 1705
4. DM Nathan 2007 Finding new treatments for diabetes-how many, how fast. how good? N Engl J Med 356 437 440
5. DJ Drucker J Philippe S Mojsov WL Chick JF Habener 1987 Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line Proc Natl Acad Sci USA 84 3434 3438
6. DJ Drucker 2006 The biology of incretin hormones Cell Metab 3 153 165
7. K Miyawaki Y Yamada H Yano 1999 Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice Proc Natl Acad Sci USA 96 14843 14847
8. LA Scrocchi TJ Brown N MaClusky 1996 Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene Nat Med 2 1254 1258
9. C Orskov A Wettergren JJ Holst 1993 Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable Diabetes 42 658 661
10. MI De C Durinx G Bal 2000 Natural substrates of dipeptidyl peptidase IV Adv Exp Med Biol 477 67 87
11. MI De AM Lambeir P Proost S Scharpe 2003 Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV Adv Exp Med Biol 524 3 17
12. R Mentlein 1999 Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides Regul Pept 85 9 24
13. CF Deacon 2004 Therapeutic strategies based on glucagon-like peptide 1 Diabetes 53 2181 2189
14. L Bouchard A Tchernof Y Deshaies 2007 ZFP36: a promising candidate gene for obesity-related metabolic complications identified by converging genomics Obes Surg 17 372 382
15. IR Konig A Ziegler 2003 Group sequential study designs in genetic-epidemiological case-control studies Hum Hered 56 63 72
16. JL Sobell LL Heston SS Sommer 1993 Novel association approach for determining the genetic predisposition to schizophrenia: case-control resource and testing of a candidate gene Am J Med Genet 48 28 35
17. JM Satagopan ES Venkatraman CB Begg 2004 Two-stage designs for gene-disease association studies with sample size constraints Biometrics 60 589 597
18. MC Vohl R Sladek J Robitaille 2004 A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men Obes Res 12 1217 1222
19. J Robitaille JP Despres L Perusse MC Vohl 2003 The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Quebec Family Study Clin Genet 63 109 116
20. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183-1197
21. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486-2497
22. JC Barrett B Fry J Maller MJ Daly 2005 Haploview: analysis and visualization of LD and haplotype maps Bioinformatics 21 263 265
23. AM Laberge J Michaud A Richter 2005 Population history and its impact on medical genetics in Quebec Clin Genet 68 287 301
24. AM Laberge 2007 Prevalence and distribution of genetic diseases in Quebec: impact of the past on the present Med Sci (Paris) 23 997 1001
25. K Aertgeerts S Ye L Shi 2004 N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding Protein Sci 13 145 154
26. V Fulop Z Szeltner L Polgar 2000 Catalysis of serine oligopeptidases is controlled by a gating filter mechanism EMBO Rep 1 277 281
27. MD Gorrell V Gysbers GW McCaughan 2001 CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes Scand J Immunol 54 249 264
28. K Ajami CA Abbott M Obradovic 2003 Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family Biochemistry 42 694 701